Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 11/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24196109 | 0.89 | HDAC1 (0.39) | DHODHMAP2K1MAP2K2HDAC3HDAC1 | |
| SCHEMBL24195828 | 0.88 | CSF1R (0.39) | DHODHMAP2K1MAP2K2HDAC3HDAC1 | |
| SCHEMBL23851383 | 0.86 | MAP2K1 (0.59) | DHODHMAP2K1MAP2K2 | |
| SCHEMBL31135614 | 0.86 | MAP2K1 (0.59) | DHODHMAP2K1MAP2K2 | |
| SCHEMBL24195652 | 0.83 | MAP2K1 (0.45) | DHODHMAP2K1MAP2K2HDAC3HDAC1 | |
| SCHEMBL24195794 | 0.83 | MAP2K1 (0.51) | MAP2K1MAP2K2HDAC3HDAC1HDAC6 | |
| SCHEMBL24195909 | 0.82 | MAP2K1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL26047886 | 0.81 | KEAP1 (0.50) | DHODHMAP2K1MAP2K2METAP2 | |
| SCHEMBL24195670 | 0.81 | MAP2K1 (0.46) | MAP2K1MAP2K2 | |
| SCHEMBL24196094 | 0.81 | MAP2K1 (0.33) | DHODHMAP2K1MAP2K2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | DHODH 3633/4885MAP2K1 4087/4885MAP2K2 3533/4885 |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CUTA, BRAF | DHODH 1123/4885MAP2K1 469/4885MAP2K2 291/4885 |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | TYR, CUTA, BRAF | DHODH 1123/4885MAP2K1 469/4885MAP2K2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.